Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma" [Cell Signal. 2024 Dec:124:111467].
Zheng L, Rajamanickam V, Wang M, Zhang H, Fang S, Linnebacher M, Abd El-Aty AM, Zhang X, Zhang Y, Wang J, Chen M, Zhao Z, Ji J. Zheng L, et al. Among authors: rajamanickam v. Cell Signal. 2024 Dec 4:111542. doi: 10.1016/j.cellsig.2024.111542. Online ahead of print. Cell Signal. 2024. PMID: 39638690 No abstract available.
Fangchinoline inhibits metastasis and reduces inflammation-induced epithelial-mesenchymal transition by targeting the FOXM1-ADAM17 axis in hepatocellular carcinoma.
Zheng L, Rajamanickam V, Wang M, Zhang H, Fang S, Linnebacher M, Abd El-Aty AM, Zhang X, Zhang Y, Wang J, Chen M, Zhao Z, Ji J. Zheng L, et al. Among authors: rajamanickam v. Cell Signal. 2024 Dec;124:111467. doi: 10.1016/j.cellsig.2024.111467. Epub 2024 Oct 10. Cell Signal. 2024. PMID: 39393566
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.
Muijlwijk T, Nijenhuis DNLM, Ganzevles SH, Brink A, Ke C, Fass JN, Rajamanickam V, Leemans CR, Koguchi Y, Fox BA, Poell JB, Brakenhoff RH, van de Ven R. Muijlwijk T, et al. Among authors: rajamanickam v. J Immunother Cancer. 2024 Jan 11;12(1):e007573. doi: 10.1136/jitc-2023-007573. J Immunother Cancer. 2024. PMID: 38212122 Free PMC article.
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.
Page DB, Pucilowska J, Chun B, Kim I, Sanchez K, Moxon N, Mellinger S, Wu Y, Koguchi Y, Conrad V, Redmond WL, Martel M, Sun Z, Campbell MB, Conlin A, Acheson A, Basho R, McAndrew P, El-Masry M, Park D, Bennetts L, Seitz RS, Nielsen TJ, McGregor K, Rajamanickam V, Bernard B, Urba WJ, McArthur HL. Page DB, et al. Among authors: rajamanickam v. NPJ Breast Cancer. 2023 Jun 21;9(1):53. doi: 10.1038/s41523-023-00541-2. NPJ Breast Cancer. 2023. PMID: 37344474 Free PMC article.
124 results